Company Scientific Advisor
Professor Kjell Alving
Scientific Advisor to the Board
Kjell Alving received a PhD degree in Pharmacology in 1990, became Associate Professor in 1994, and Full Professor in 2003, all at Karolinska Institutet, Stockholm. Alving is Professor of Respiratory Pharmacology at Uppsala University since 2014. He has also held positions within life science industry: 1982-1986 at Pharmacia (Research Engineer, basic allergy research), and 2007-2014 at Aerocrine (Chief Science Officer) where he was a member of the Management Team between 2007-2011.
Alving and colleagues were first to show elevated levels of exhaled nitric oxide (FeNO) in subjects with asthma (1993). He has held several patents within the field of nitric oxide, and was a co-founder of Aerocrine, a company that was publicly listed (Stockholm OMX) between 2007-2015, and purchased by Circassia in 2015. Alving has supervised 20 PhD students, and he has published 175 original articles, and 30 review articles, editorials etc, and has had more than 200 referee commissions in international journals, including the topmost ranked journals within the Respiratory and Allergy fields.